LOGIN  |  REGISTER

Latest Pharmaceutical Stock News

FILTER BY TOPIC:     Clinical Trials   FDA Updates   FDA Approvals   Patents        List of All Pharmaceutical Stocks  

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

February 25
Last Trade: 32.96 0.47 1.45

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies  Allergic reactions can be life-threatening and it is estimated that food-related...Read more


Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

February 23
Last Trade: 129.45 0.19 0.15

Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small cell lung cancer (NSCLC) based on positive overall survival results RAHWAY, N.J. / Feb 23, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s...Read more


AstraZeneca: MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

February 23
Last Trade: 65.83 1.70 2.65

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses WILMINGTON, Del. / Feb 23, 2024 / Business Wire / Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with EGPA were published in the New England Journal of Medicine today,1 as the first head-to-head trial of biologics in patients with EGPA,2 and the first to demonstrate that more than half of patients achieved...Read more


Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

February 23
Last Trade: 51.66 0.33 0.64

Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly doubled the percentage of patients achieving primary endpoint of both transfusion independence and hemoglobin increase vs. epoetin alfa PRINCETON, N.J. / Feb 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the...Read more


Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

February 23
Last Trade: 223.32 0.84 0.38

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use...Read more


Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

February 23
Last Trade: 15.07 0.21 1.41

Apraglutide nutritional data from STARS Nutrition Phase 2 study in adult patients who have short bowel syndrome with intestinal failure and colon-in-continuity will be highlighted in an oral presentation Additional data on apraglutide from previously completed Phase 1 and Phase 2 studies will also be highlighted in poster presentations BOSTON / Feb 23, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused...Read more


Biofrontera Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

February 23
Last Trade: 0.92 -0.08 -7.54

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 23, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the...Read more


AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

February 22
Last Trade: 178.09 1.34 0.76

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix...Read more


Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

February 22
Last Trade: 9.18 -0.12 -1.29

Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the...Read more


Collegium Pharmaceutical Reports Record Fourth Quarter and Full-Year 2023 Financial Results

February 22
Last Trade: 36.35 3.54 10.79

Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million  Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million  Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million  Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million  Conference Call Scheduled for Today at 4:30 p.m....Read more


Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

February 22
Last Trade: 0.89 -0.06 -6.06

PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per...Read more


Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

February 21
Last Trade: 5.51 0.06 1.10

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who...Read more


Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

February 21
Last Trade: 2.74 -0.06 -2.14

Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president...Read more


Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

February 21
Last Trade: 1.62 0.10 6.58

Topline Results Expected in Q2 2024 Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced completion of patient enrollment in its Phase II open-label pilot study...Read more


Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

February 21
Last Trade: 1.64 0.03 1.55

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million and annual revenue of $81.8 million Updated Phase 1 trial investigating sudocetaxel zendusortide in advanced ovarian cancer reaches key milestone with enrollment of first six patients Guidance for 2024 set to...Read more


Johnson & Johnson: TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

February 20
Last Trade: 161.84 1.39 0.87

Biweekly dosing with TECVAYLI®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W)...Read more


AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer

February 20
Last Trade: 178.09 1.34 0.76

Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman Transition will occur on July 1, 2024 NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez, who has served as...Read more


Bristol-Myers Squibb: U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated...

February 20
Last Trade: 51.66 0.33 0.64

U.S. FDA has assigned a target action date of June 21, 2024 Application based on results from the Phase 1/2 KRYSTAL-1 study PRINCETON, N.J. / Feb 20, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental new drug application (sNDA) for KRAZATI® (adagrasib) in combination with cetuximab for the treatment of patients...Read more


Gilead Sciences to Present at Upcoming Investor Conferences

February 20
Last Trade: 73.55 0.77 1.06

FOSTER CITY, Calif. / Feb 20, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 5 at 12:50pm Eastern Time Leerink Partners Global Biopharma Conference on Tuesday, March 12 at 10:00am Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 13 at 11:15am...Read more


Teva Pharmaceuticals Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

February 20
Last Trade: 12.89 -0.16 -1.23

Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-’574)1 Anti-TL1A (TEV-’574) was shown to be safe and well-tolerated, with a low incidence of antidrug antibodies2 Data support the ongoing Phase 2b clinical investigation of anti-TL1A (TEV-’574) in inflammatory bowel disease3 TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 20, 2024 / Business Wire / Teva Pharmaceuticals, a...Read more


Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

February 20
Last Trade: 18.50 -0.05 -0.27

JERSEY CITY, N.J. / Feb 20, 2024 / Business Wire / Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary. HADLIMA is an FDA-approved biosimilar to HUMIRA for the treatment of specific autoimmune or autoinflammatory conditions such as rheumatoid...Read more


ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

February 20
Last Trade: 59.13 0.98 1.69

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows: Date:   Tuesday, March 12, 2024 Time:   2:20 p.m. ET Webcast:   Click Here To schedule...Read more


Scilex Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

February 20
Last Trade: 1.75 0.01 0.57

The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%.2 There are currently no approved medical treatments for neck pain in the U.S. The study was a randomized, double-blind, placebo-controlled crossover trial performed at four U.S. military, Veterans Administration, academic, and private practice sites, in which 76 patients were randomized to receive either a placebo...Read more


ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

February 20
Last Trade: 4.96 0.00 0.00

Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test. BE-Smart is a novel diagnostic test that is intended to detect and quantify early signs of certain types of cancer in individuals...Read more


Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

February 20
Last Trade: 0.59 0.04 6.31

MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator...Read more


Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

February 20
Last Trade: 1.64 0.03 1.55

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model Weekly administration of single agent sudocetaxel zendusortide demonstrated superior tumor growth inhibition and immune cell infiltration compared to docetaxel in “cold” murine tumor model Preclinical results suggest new...Read more


Biofrontera Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

February 20
Last Trade: 0.92 -0.08 -7.54

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the...Read more


AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

February 19
Last Trade: 178.09 1.34 0.76

A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD) Oral data presentations include a new post-hoc analysis of clinical and endoscopic outcomes from the SEQUENCE trial comparing risankizumab (SKYRIZI®) versus ustekinumab, results from the COMMAND...Read more


AstraZeneca: Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

February 19
Last Trade: 65.83 1.70 2.65

Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer WILMINGTON, Del. / Feb 19, 2024 / Business Wire / AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult...Read more


AstraZeneca: TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

February 19
Last Trade: 65.83 1.70 2.65

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting WILMINGTON, Del. / Feb 19, 2024 / Business Wire / Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III...Read more


European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

February 19
Last Trade: 27.76 0.21 0.76

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU NEW YORK / Feb 19, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis...Read more


Amgen To Host Conference Call On Rare Disease

February 19
Last Trade: 289.18 4.00 1.40

THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president...Read more


FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

February 16
Last Trade: 32.96 0.47 1.45

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placebo More than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once Detailed OUtMATCH...Read more


AstraZeneca: TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

February 16
Last Trade: 65.83 1.70 2.65

Approval based on FLAURA2 results which showed TAGRISSO plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care WILMINGTON, Del. / Feb 16, 2024 / Business Wire / AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small...Read more


Incannex Healthcare Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

February 16
Last Trade: 4.77 -1.62 -25.35

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and...Read more


Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

February 15
Last Trade: 27.76 0.21 0.76

NEW YORK / Feb 15, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint. During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic approach,...Read more


Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 15
Last Trade: 18.50 -0.05 -0.27

Full year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency Full year 2023 diluted earnings per share of $3.99 and non-GAAP Adjusted diluted earnings per share of $4.14 Full year 2023 Adjusted EBITDA of $1.9 billion, representing a 31.0% Adjusted EBITDA margin Full year 2024 financial guidance ranges provided; full year revenue range of $6.2 billion to $6.5 billion and Adjusted EBITDA margin in the range of...Read more


Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

February 15
Last Trade: 15.07 0.21 1.41

LINZESS® (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year  2023 Ironwood revenue of $443 million, driven primarily by $430 million in U.S. LINZESS collaboration revenue  Continues to expect topline results from the STARS Phase III study of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) in...Read more


Pacira BioSciences Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

February 15
Last Trade: 30.04 0.07 0.23

Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator  Significantly greater proportion of opioid-free patients receiving EXPAREL  TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the publication of its...Read more


Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

February 15
Last Trade: 10.94 -0.18 -1.62

NASHVILLE, Tenn. & TORONTO / Feb 15, 2024 / Business Wire / Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada...Read more


Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

February 15
Last Trade: 1.62 0.10 6.58

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces...Read more


Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

February 15
Last Trade: 1.64 0.03 1.55

Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six participants in Part 3 of its...Read more


Sunshine Biopharma Announces Closing of $10.0 Million Underwritten Public Offering

February 15
Last Trade: 0.05 -0.0076 -12.65

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately $10.0 million, before deducting underwriting discounts and other...Read more


U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

February 14
Last Trade: 51.66 0.33 0.64

Application based on results from the TRIDENT-1 and CARE trials, in which Augtyro demonstrated clinically meaningful response rates If approved, Augtyro will provide a new, next-generation option for patients with NTRK-positive locally advanced or metastatic solid tumors who have high unmet medical needs The U.S. Food and Drug Administration assigned a target action date of June 15, 2024 PRINCETON, N.J. / Feb 14, 2024 / Business Wire...Read more


Grifols announces positive topline phase 3 fibrinogen clinical trial results

February 14
Last Trade: 9.13 0.43 4.94

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profile Regulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an...Read more


Elite Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

February 14
Last Trade: 0.15 -0.01 -8.92

Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter"). Consolidated revenues for...Read more


ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

February 14
Last Trade: 4.96 0.00 0.00

Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has...Read more


Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

February 14
Last Trade: 1.65 -0.01 -0.60

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its...Read more


Evoke Pharma Announces Closing of $7.5 Million Public Offering

February 14
Last Trade: 0.64 -0.03 -4.17

SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross...Read more


Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

February 13
Last Trade: 32.96 0.47 1.45

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide. The collaboration between RTD and PathAI helps advance precision medicine by bringing together...Read more


Zoetis Reports Fourth Quarter and Full Year 2023 Results

February 13
Last Trade: 197.21 0.55 0.28

For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023 Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023 For Full Year 2023,...Read more


Amneal Pharmaceuticals to Participate at Upcoming Investor Conference

February 13
Last Trade: 5.80 0.11 1.93

BRIDGEWATER, N.J. / Feb 13, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one meetings to follow A live webcast of the presentation will be accessible through the Investor Relations section of...Read more


Neighbourly Pharmacy Announces Strong Third Quarter Results

February 13
Last Trade: 18.41 -0.01 -0.05

Company delivers strong pharmacy same store sales performance as its retail footprint expands to 294 locations TORONTO, Feb. 13, 2024 /CNW/ - Neighbourly Pharmacy Inc. ("Neighbourly" or the "Company") (TSX: NBLY), Canada's largest and fastest growing network of independent pharmacies, today announced its financial results for the sixteen-week period ended December 30, 2023 (the "third quarter 2024"). "Neighbourly's third...Read more


Valeo Pharma Announces Board Of Directors Changes

February 13
Last Trade: 0.19 0.00 0.00

MONTREAL, Feb. 13, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. "We are pleased to welcome Robert and Charles to...Read more


Shuttle Pharmaceuticals Announces Its Intent to Pursue a Rights Offering

February 13
Last Trade: 0.36 0.001 0.28

ROCKVILLE, Md., Feb. 13, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("SHPH" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), along with its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation ("Diagnostics"), today announced its intent to commence a Rights...Read more


Sunshine Biopharma Announces Pricing of $10.0 Million Underwritten Public Offering

February 13
Last Trade: 0.05 -0.0076 -12.65

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting fees and...Read more


Merck: Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumou...

February 12
Last Trade: 129.45 0.19 0.15

Approval is based on the Phase 3 KEYNOTE-811 Trial KIRKLAND, QC, Feb. 12, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced...Read more


AbbVie Completes Acquisition of ImmunoGen

February 12
Last Trade: 178.09 1.34 0.76

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand...Read more


Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 12
Last Trade: 73.55 0.77 1.06

Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024  Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC  Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases  FOSTER CITY, Calif. & NEWARK, Calif. / Feb 12, 2024 /...Read more


FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

February 12
Last Trade: 14.62 -0.02 -0.14

12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and Intermittent Symptoms of Choking and Difficult or Painful Swallowing OSAKA, Japan & CAMBRIDGE, Mass. / Feb 12, 2024 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA)...Read more


Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 12
Last Trade: 223.32 0.84 0.38

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized...Read more


Amgen to Present at 34th Annual Oppenheimer Healthcare Life Sciences Conference

February 9
Last Trade: 289.18 4.00 1.40

THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon, executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney, senior vice president of...Read more


Catalent Reports Second Quarter Fiscal 2024 Results

February 9
Last Trade: 58.77 0.37 0.63

Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID-related revenue of ~$260 million in Q2’23 and ~$75 million in Q2’24, increased 8% compared to Q2'23. Q2'24 net loss of $(204) million compared to $81 million of net income in Q2'23 due primarily to a decline in COVID-related demand. Q2'24 Adjusted EBITDA(1) of $124 million...Read more


Embecta Reports First Quarter Fiscal 2024 Financial Results

February 9
Last Trade: 14.84 0.09 0.61

PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2023. "Building on our performance during 2023, embecta delivered strong results for the first quarter of 2024," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "During the first quarter, I am...Read more


Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

February 9
Last Trade: 0.64 -0.03 -4.17

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross...Read more


Merck Canada Announces Collaboration With Vector Institute To Further Advance Its Artificial Intelligence Capabilities And Drive Innovation In Healthcare

February 8
Last Trade: 129.45 0.19 0.15

KIRKLAND, QC, Feb. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an independent not-for-profit corporation dedicated to advancing the field of artificial intelligence (AI) through world-class research.  This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and...Read more


AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

February 8
Last Trade: 178.09 1.34 0.76

VYALEV is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease (aPD) in Canada. Advanced Parkinson's disease patients now have a non-surgical treatment option that addresses an unmet need within this community. In clinical trials, patients taking VYALEV achieved the primary endpoint of a reduction in motor fluctuations and morning akinesia, as well as improvements...Read more


AstraZeneca Full year and Q4 2023 Financial Results

February 8
Last Trade: 65.83 1.70 2.65

Strong growth and pipeline momentum with three new medicines approved since the third quarter CAMBRIDGE, United Kingdom / Feb 08, 2024 / Business Wire / AstraZeneca: Revenue and EPS summary     FY 2023   Q4 2023         % Change       %...Read more


Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

February 8
Last Trade: 14.62 -0.02 -0.14

Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial TAK-861 Was Found to be Generally Safe and Well-Tolerated Results Will be Presented at an Upcoming Scientific Congress OSAKA, Japan & CAMBRIDGE, Mass. / Feb 08, 2024 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating...Read more


Walgreens Boots Alliance Announces Leadership Appointments

February 8
Last Trade: 21.73 0.16 0.74

Chief Executive Officer Tim Wentworth solidifies the Walgreens Boots Alliance Executive Committee New executive appointments deepen healthcare expertise, position company for accelerated growth and profitability  Mary Langowski joins WBA to lead U.S. Healthcare segment Manmohan Mahajan, interim since July 2023, appointed permanent chief financial officer Elizabeth Burger joins WBA as chief human resources officer DEERFIELD,...Read more


Veru Reports Fiscal 2024 First Quarter Financial Highlights

February 8
Last Trade: 0.59 0.04 6.31

Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Company to initiate Phase 2b obesity study by April 2024 Company completed public offering for net proceeds of $35.2 million, bringing total cash to $40.6 million at December 31, 2023 Company to host conference call and webcast today at 8:00 a.m....Read more


Optimi Health Announces Non-Brokered Private Placement

February 8
Last Trade: 0.31 0.02 6.90

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 5,000,000 units (each a “Unit”) at CAD$0.30 per Unit for gross proceeds of...Read more


Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

February 8
Last Trade: 0.15 -0.0076 -4.95

Revenues increased 7% compared to quarter from prior year and 15% from prior quarter Improvement in gross margin for quarter of 19% compared to prior year Improvement in net loss for quarter of $1.0 million compared to prior year BOULDER, CO / ACCESSWIRE / February 8, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of...Read more


Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

February 7
Last Trade: 51.66 0.33 0.64

Applications based on results from CheckMate -77T, the company’s second positive Phase 3 randomized trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer The perioperative Opdivo-based regimen demonstrated significant improvement in event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo The U.S. Food and Drug Administration...Read more


Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7
Last Trade: 12.62 0.02 0.16

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14 at 2:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will...Read more


Phibro Animal Health Reports Second Quarter Results, Updates Financial Guidance

February 7
Last Trade: 12.88 0.04 0.31

TEANECK, N.J. / Feb 07, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) Net sales of $249.9 million, an increase of $5.3...Read more


Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results

February 7
Last Trade: 1.70 0.01 0.59

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third...Read more


DURECT to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7
Last Trade: 0.98 0.02 1.87

CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024. Presentation details are as follows: Date and Time:              Wednesday, February 14, 10:40 a.m....Read more


Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

February 6
Last Trade: 769.54 -0.10 -0.01

Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic...Read more


Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

February 6
Last Trade: 178.09 1.34 0.76

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif.,...Read more


AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

February 6
Last Trade: 65.83 1.70 2.65

New facility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platforms WILMINGTON, Del. / Feb 06, 2024 / Business Wire / AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will...Read more


Amgen Reports Fourth Quarter And Full Year 2023 Financial Results

February 6
Last Trade: 289.18 4.00 1.40

THOUSAND OAKS, Calif., Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. "2023 was another year of performance and progress for our company," said Robert A. Bradway, chairman and chief executive officer. "Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen significant...Read more


Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

February 6
Last Trade: 73.55 0.77 1.06

Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 FOSTER CITY, Calif. / Feb 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth...Read more


GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

February 6
Last Trade: 42.22 0.06 0.14

Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical conditions are at increased risk for RSV disease1,2,3 GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk US FDA has set a Prescription Drug User Fee Act action date of June 7,...Read more


HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

February 6
Last Trade: 15.72 0.06 0.38

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary Series Session on February 6,...Read more


Knight Therapeutics Announces Launch of Bijuva® in Canada

February 6
Last Trade: 5.51 0.06 1.10

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada. BIJUVA® is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus. VMS affects 60% to 80% of women entering menopause1 and are...Read more


Phibro Animal Health Announces Chief Financial Officer Changes

February 6
Last Trade: 12.88 0.04 0.31

TEANECK, N.J. / Feb 06, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024. Mr. Richard Johnson, who is currently serving as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity...Read more


HLS Therapeutics Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

February 6
Last Trade: 3.98 -0.07 -1.73

Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, Veterans Affairs and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples. Approximately 14% of all Canadians live in British Columbia1. Pacific Blue Cross, British Columbia's largest private health plan, also expected to reimburse Vascepa starting in...Read more


Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

February 6
Last Trade: 0.59 0.04 6.31

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical function while augmenting fat loss in sarcopenic obese or overweight elderly patients on GLP-1 drug for weight loss Phase 2b clinical trial is expected to...Read more


Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

February 5
Last Trade: 123.45 -1.07 -0.86

Bagsværd, Denmark, 5 February 2024 – Novo Nordisk (NYSE: NVO) today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Pharma Gainers

 
CompanyChangeLast Trade
Amgen 4.00 1.40 $289.18
Collegium Pharmaceutical 3.54 10.79 $36.35
AstraZeneca 1.70 2.65 $65.83
Amphastar Pharmaceuticals 1.50 2.89 $53.41
Johnson & Johnson 1.39 0.87 $161.84
AbbVie 1.34 0.76 $178.09
Supernus Pharmaceuticals 1.12 4.01 $29.06
Novartis 1.10 1.07 $103.90
PTC Therapeutics 1.03 3.96 $27.07
ANI Pharmaceuticals 0.98 1.69 $59.13
Sanofi 0.97 2.03 $48.77
Biogen 0.84 0.38 $223.32
Dr. Reddy's Laboratories 0.78 1.02 $77.59
Gilead Sciences 0.77 1.06 $73.55
LifeMD 0.65 9.70 $7.35
Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...

CLICK TO LEARN MORE
List of Pharmaceutical Stocks

Pharmaceutical Stocks

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB